Recent Updates
Recently added Catalysts
HCM Positive Sentiment Score: 65/100

Intended r etirement of Independent Non-executive Director and changes of composition of board committees Hong Kong, Shanghai & Florham Park, NJ - Friday

Key Takeaway: HUTCHMED (China) Limited announced the upcoming retirement of Professor Mok Shu Kam, Tony, an Independent Non-executive Director, who will not seek re-election at the annual general meeting on May 12, 2026. Professor Mok's tenure will conclude, marking nearly nine years of service, during which he played a significant role in strengthening the Board and guiding the Company's scientific efforts. Alongside his retirement, there will be changes to the composition of board committees pending re-elections at the AGM. The Board expressed gratitude for Professor Mok's contributions, emphasizing the impact of his leadership on HUTCHMED’s strategy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Professor Mok has served with distinction, contributing to the growth of the Company.
  • His leadership has been instrumental in strengthening the Board composition.
  • He provides invaluable perspective to the long-term strategy of HUTCHMED.

Full Press Release Details

Intended retirement of Independent Non-executive Director
and changes of composition of board committees
Hong Kong, Shanghai & Florham Park, NJ - Friday, March 6, 2026: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 ("AGM"). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight years, approaching the nine-year cap on the tenure of independent non-executive directors under the Hong Kong Listing Rules. Consequently, he will cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon his retirement, he will also step down from his roles as chairman and member of the board committees of the Company.
In connection with the intended retirement of Professor Mok from the Board, the Board has approved the following changes to the composition of the board committees and the Senior and Lead Independent Non-executive Director of the Company, effective from the conclusion of the AGM, subject to the respective Directors being re-elected as Directors by the shareholders at the AGM:-
Each of Dr Bhatia, Dr Hu and Professor Tan is currently an Independent Non-executive Director of the Company.
Dr Dan Eldar, the Chairman of HUTCHMED, said: "Professor Mok has served with distinction as an Independent Non-executive Director and as chairman of both the Nomination Committee and the Technical Committee. His leadership has been instrumental in strengthening the Board composition, and guiding the scientific and clinical development programs. His internationally recognized expertise in oncology has brought invaluable perspective to the long term strategy of the Company. The Board sincerely thanks Professor Mok for his significant contributions to the growth of the Company, and we wish him all the best in his future endeavours."
Pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules, Professor Mok has confirmed that he has no disagreement with the Board and that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with his retirement from the Board.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to HUTCHMED's board of directors are not e ective in their respective positions, the di iculty in locating and recruiting suitable candidates for its board of directors and the management di iculties which may arise from changes in HUTCHMED's board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, on A M and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
Investor Enquiries +852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting - +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick - Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000

Frequently Asked Questions

When will Professor Mok retire from HUTCHMED's Board?

Professor Mok will retire from HUTCHMED's Board after the AGM on May 12, 2026.

How long has Professor Mok served as a director?

Professor Mok has served as an Independent Non-executive Director for over eight years.

What roles will Professor Mok step down from?

Upon retirement, Professor Mok will resign from his chairman and committee member roles.

What did Dr. Dan Eldar say about Professor Mok?

Dr. Dan Eldar praised Professor Mok for his distinguished service and invaluable expertise.

Did Professor Mok have any disagreements with the Board?

Professor Mok confirmed he has no disagreements with the Board regarding his retirement.

Last updated: Mar 6, 2026